Correspondence 0001214659-23-016477 from Biodexa Pharmaceuticals Plc (BDRX)
Biodexa Pharmaceuticals Plc
Date: Dec. 15, 2023 · CIK: 0001643918 · Accession: 0001214659-23-016477
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-274895
Letter
Biodexa Pharmaceuticals Plc
1 Caspian Point
Caspian Way
Cardiff, CF10 4DQ
United Kingdom
December 15, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention: Doris Stacey Gama
Re: Biodexa Pharmaceuticals Plc (the “Company”)
Registration Statement on Form F-1 (File No. 333-274895)
Originally Filed October 6, 2023
Ladies and Gentlemen:
Pursuant to Rule 461(a) under the Securities Act of 1933, as amended (the “Act”), the Company hereby respectfully requests that the Securities and Exchange Commission accelerates the effective date of the above-referenced Registration Statement on Form F-1 (the “Registration Statement”) and declares the Registration Statement effective as of 5:30 p.m. Eastern Time, on December 18, 2023, or as soon as practicable thereafter. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
We request that we be notified of such effectiveness by a telephone call to Jason S. McCaffrey at (617) 348-4416 of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Company, and we request that such effectiveness also be confirmed in writing.
Very truly yours,
BIODEXA PHARMACEUTICALS PLC
Show Raw Text
CORRESP
1
filename1.htm
Biodexa Pharmaceuticals Plc
1 Caspian Point
Caspian Way
Cardiff, CF10 4DQ
United Kingdom
December 15, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention: Doris Stacey Gama
Re: Biodexa Pharmaceuticals Plc (the “Company”)
Registration Statement on Form F-1 (File No. 333-274895)
Originally Filed October 6, 2023
Ladies and Gentlemen:
Pursuant to Rule 461(a) under the Securities Act
of 1933, as amended (the “Act”), the Company hereby respectfully requests that the Securities and Exchange Commission accelerates
the effective date of the above-referenced Registration Statement on Form F-1 (the “Registration Statement”) and declares
the Registration Statement effective as of 5:30 p.m. Eastern Time, on December 18, 2023, or as soon as practicable thereafter. In making
this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
We request that we be notified of such effectiveness
by a telephone call to Jason S. McCaffrey at (617) 348-4416 of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Company,
and we request that such effectiveness also be confirmed in writing.
Very truly yours,
BIODEXA PHARMACEUTICALS PLC
By:
/s/ Stephen Stamp
Name:
Stephen Stamp
Title:
Chief Executive Officer & Chief Financial Officer
cc:
Jason S. McCaffrey, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.